Why Should You Put Evolus Inc. (NASDAQ: EOLS) On Your Portfolio?


BlackRock Fund Advisors recently announced the acquisition of new stake in Evolus Inc. (NASDAQ:EOLS). The institutional investor has increased its shareholding in the Healthcare company by 17.40% to 1.79 million shares with purchase of 0.27 million shares. This fresh investment now brings its stake to 5.32% valued currently at $5.84 million. In addition, Schroder Investment Management No. raised its holdings by 88292.0 to 1.13 million shares. And The Vanguard Group, Inc. has lifted its position by 0.06% or 639.0 shares – to 1.05 million shares.

With over 1.04 million Evolus Inc. (EOLS) shares trading Monday and a closing price of $3.41 on the day, the dollar volume was approximately $3.54 million. The shares have shown a negative weekly performance of -12.56% and its price on 08/24/20 lost nearly -3.94%. Currently, there are 33.73M common shares owned by the public and among those 22.33M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for EOLS have a consensus price objective of $10.63. The analysts have set the share’s price value over the next 12 months at a high of $35.00 and a low of $4.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Evolus Inc. stock is 2.10 for the next 12 months. But an upside of 90.26% will see the stock hit the forecast high price target while mean target price for the stock is $7.00.

Insiders at the company have transacted a total of 11 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 390,090 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 8,701,788 shares.

The top 3 mutual fund holders in Evolus Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and iShares NASDAQ Biotechnology ETF. Vanguard Total Stock Market Index owns 0.6 million shares of the company’s stock, all valued at over $1.94 million. iShares Russell 2000 ETF sold 21658.0 shares to see its total holdings shrink to 0.46 million shares valued at over $1.51 million and representing 1.38% of the shares outstanding. iShares NASDAQ Biotechnology ETF sold 2673.0 shares to bring its total holdings to over 0.35 million shares at a value of $1.13 million. iShares NASDAQ Biotechnology ETF now owns shares totaling to 1.03% of the shares outstanding.

Shares of Evolus Inc. (NASDAQ: EOLS) opened at $3.52, down -$0.03 from a prior closing price of $3.55. However, the script later closed the day at $3.41, down -3.94%. The company’s stock has a 5-day price change of -12.56% and -26.03% over the past three months. EOLS shares are trading -71.98% year to date (YTD), with the 12-month market performance down to -77.21% lower. It has a 12-month low price of $3.00 and touched a high of $19.00 over the same period. Currently, 1.04 million shares have been traded, compared to an average intraday trading volume of 1.12 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.12%, -16.44%, and -52.95% respectively.

Institutional ownership of Evolus Inc. (NASDAQ: EOLS) shares accounts for 28.60% of the company’s 33.73M shares outstanding. Mutual fund holders own 17.44%, while other institutional holders and individual stakeholders account for 61.16% and 10.09% respectively.

It has a market capitalization of $123.82M. The earnings-per-share (ttm) stands at -$2.67. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.19% over the week and 6.58% over the month.

Analysts forecast that Evolus Inc. (EOLS) will achieve an EPS of $SOLLENSYS CORP for the current quarter, $0.13 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Eaton Vance Enhance Equity Inco while analysts give the company a high EPS estimate of $Equity Lifestyle Properties, In. Comparatively, EPS for the current quarter was $ExlService Holdings, Inc. a year ago. Earnings per share for the fiscal year are expected to decrease by -66.00%, and 69.50% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Evolus Inc. (EOLS) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 2 of the 8 advise that investors “hold,” and 1 rated it as a “Sell.”

Looking at the support for the EOLS, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on July 07, 2020, with the firm’s price target at $8-$3. Mizuho coverage for the Evolus Inc. (EOLS) stock in a research note released on February 06, 2020 offered a Buy rating with a price target of. SVB Leerink was of a view on November 26, 2019 that the stock is Outperform, while Mizuho gave the stock Buy rating on September 05, 2019, issuing a price target of $30. Wells Fargo on their part issued Market Perform rating on June 28, 2019.


Please enter your comment!
Please enter your name here